{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:25:12Z","timestamp":1786922712672,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A phase I study was conducted to determine the optimal dose of irinotecan in short-course chemoradiotherapy (SCCRT) using S-1\/irinotecan and short-course radiotherapy (SCRT) for the development of a new total neoadjuvant therapy (TNT) regimen that is safe, effective, and has a low patient burden for locally advanced rectal cancer (LARC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The objective of this study was to ascertain the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan in SCCRT for locally advanced rectal cancer. The assessment of dose-limiting toxicity (DLT) was conducted over a 14-day period following treatment administration. The patient received a 14-day course of chemotherapy, with S-1 administered from the first to the fifth day and from the eighth to the twelfth day. Irinotecan was administered on the first and eighth days of treatment. The radiotherapy regimen was initiated with a total dose of 25\u00a0Gy, administered in five fractions from the eighth to twelfth day.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen patients received SCRT in conjunction with S-1 and escalating doses of irinotecan (40\u201360\u00a0mg\/m\u00b2). All patients completed the SCCRT protocol. At a dose of 60\u00a0mg\/m\u00b2, DLT occurred in all patients, thereby establishing this dosage as the MTD. At a dose of 50\u00a0mg\/m\u00b2, DLT was observed in two of six patients, thereby establishing this dose as the RD. The most prevalent Grade\u2009\u2265\u20093 adverse event was diarrhea. All patients received CapeOX-based consolidation chemotherapy. Among the 11 surgical cases, the R0 resection rate was 100%, with a pathological complete response in 27.3% and downstaging in 90.9%. Three patients demonstrated a complete clinical response and underwent non-operative management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The safety and feasibility of administering SCCRT with S-1\/irinotecan at a 50\u00a0mg\/m\u00b2 irinotecan dose have been demonstrated. These findings support further investigation of this regimen in a TNT setting for rectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The present study was duly registered with the Japan Clinical Trials Registry (jRCT s031210461). URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/jrct.mhlw.go.jp\/re\" ext-link-type=\"uri\">https:\/\/jrct.mhlw.go.jp\/re<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02872-3","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:56:10Z","timestamp":1781085370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The phase I trial of preoperative short-course chemoradiotherapy with S-1\/irinotecan and short-course radiation in locally advanced lower rectal cancer (SHOWTIME study)"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-8358","authenticated-orcid":false,"given":"Ken","family":"Kojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamanashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Naitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2872_CR1","unstructured":"Management-Screening. Diagnosis and treatment (MND), noncommunicable diseases, rehabilitation and disability (NCD). WHO global survey on the inclusion of cancer care in health-benefit packages, 2020\u20132021. World Health Organization; 2024 Mar."},{"issue":"2","key":"2872_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.radonc.2014.10.006","volume":"113","author":"A Sainato","year":"2014","unstructured":"Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113(2):223\u20139.","journal-title":"Radiother Oncol"},{"issue":"2","key":"2872_CR3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","volume":"15","author":"J-F Bosset","year":"2014","unstructured":"Bosset J-F, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun R-J, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184\u201390.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2872_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdu560","volume":"26","author":"AJ Breugom","year":"2015","unstructured":"Breugom AJ, van Gijn W, Muller EW, Berglund \u00c5, van den Broek CBM, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696\u2013701.","journal-title":"Ann Oncol"},{"issue":"1","key":"2872_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM-K, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29\u201342.","journal-title":"Lancet Oncol"},{"issue":"15","key":"2872_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C, Jiang L-M, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(15):1681\u201392.","journal-title":"J Clin Oncol"},{"key":"2872_CR7","doi-asserted-by":"crossref","unstructured":"van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM-K, et al. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. Radiother Oncol. 2020 June;147:75\u201383.","DOI":"10.1016\/j.radonc.2020.03.011"},{"issue":"2","key":"2872_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.radonc.2016.06.002","volume":"120","author":"T Sato","year":"2016","unstructured":"Sato T, Hayakawa K, Tomita N, Noda M, Kamikonya N, Watanabe T, et al. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1). Radiother Oncol. 2016;120(2):222\u20137.","journal-title":"Radiother Oncol"},{"key":"2872_CR9","unstructured":"TNM Classification of Malignant Tumours, 8th edition https:\/\/www.uicc.org\/resources\/tnm-classification-malignant-tumours-8th-edition"},{"key":"2872_CR10","doi-asserted-by":"crossref","unstructured":"Nakamura T, Yamashita K, Sato T, Ema A, Naito M, Watanabe M. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. Int J Radiat Oncol Biol Phys. 2014 July 1;89(3):547\u201355.","DOI":"10.1016\/j.ijrobp.2014.03.007"},{"issue":"1","key":"2872_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1\u201342.","journal-title":"Int J Clin Oncol"},{"key":"2872_CR12","doi-asserted-by":"crossref","unstructured":"Nakata E, Fukushima M, Takai Y, Nemoto K, Ogawa Y, Nomiya T, et al. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1\/FU human colon cancer xenografts resistant to 5-FU. Oncol Rep. 2006 Sept;16(3):465\u201371.","DOI":"10.3892\/or.16.3.465"},{"issue":"10 Suppl 5","key":"2872_CR13","first-page":"39","volume":"13","author":"AY Chen","year":"1999","unstructured":"Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncol (Williston Park). 1999;13(10 Suppl 5):39\u201346.","journal-title":"Oncol (Williston Park)"},{"issue":"23","key":"2872_CR14","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40(23):2546\u201356.","journal-title":"J Clin Oncol"},{"issue":"3 Suppl 5","key":"2872_CR15","first-page":"37","volume":"15","author":"TA Rich","year":"2001","unstructured":"Rich TA, Kirichenko AV. Camptothecin schedule and timing of administration with irradiation. Oncol (Williston Park). 2001;15(3 Suppl 5):37\u201341.","journal-title":"Oncol (Williston Park)"},{"issue":"5","key":"2872_CR16","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S0360-3016(03)00326-2","volume":"56","author":"V Voelter","year":"2003","unstructured":"Voelter V, Stupp R, Matter M, Gillet M, Bouzourene H, Leyvraz S, et al. Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. Int J Radiat Oncol Biol Phys. 2003;56(5):1288\u201394.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2872_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ijrobp.2015.08.037","volume":"93","author":"M Jung","year":"2015","unstructured":"Jung M, Shin SJ, Koom WS, Jung I, Keum KC, Hur H, et al. A randomized phase 2 study of neoadjuvant chemoradiaton therapy with 5-fluorouracil\/leucovorin or irinotecan\/S-1 in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;93(5):1015\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02872-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02872-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02872-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:51:49Z","timestamp":1786920709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02872-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02872-3","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present trial was conducted in accordance with the ethical principles of the Declaration of Helsinki, the Japanese Clinical Research Act, related notifications, and this protocol. The legally mandated materials, including the research protocol and implementation plan, underwent thorough review and approval by the Clinical Research Review Committee of Tokai University (N12021003). Prior to enrollment, informed consent was obtained from all patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"109"}}